Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High – Time to Buy?
03:32am, Sunday, 21'st Dec 2025
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report)'s share price hit a new 52-week high during trading on Friday. The company traded as high as $43.73 and last traded at $42.7
Barry Quart Sells 20,129 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock
04:44am, Friday, 19'th Dec 2025
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) Director Barry Quart sold 20,129 shares of the firm's stock in a transaction on Monday, December 15th. The shares were sold
Fisher Asset Management LLC Has $2.83 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA
04:12am, Saturday, 06'th Dec 2025
Fisher Asset Management LLC lowered its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) by 29.1% during the second quarter, according to its most recent Form 13F filing with the SEC
AXQ Capital LP Makes New $289,000 Investment in Kiniksa Pharmaceuticals International, plc $KNSA
03:34am, Tuesday, 25'th Nov 2025
AXQ Capital LP bought a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm bought
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
04:01pm, Wednesday, 12'th Nov 2025
LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the Jefferies Global Healthcare Conference in Londo
New Strong Sell Stocks for Oct. 30th
09:26am, Thursday, 30'th Oct 2025
EQX, GDEN and KNSA have been added to the Zacks Rank #5 (Strong Sell) List on October 30, 2025.
Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage
09:05am, Thursday, 30'th Oct 2025
Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis, driving recurring revenue and strong growth. Q3 FY2025 ARCALYST revenue was $180
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2025 Earnings Call Transcript
11:41am, Tuesday, 28'th Oct 2025
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Jonathan Kirshenbaum - Investor Relations Officer Sanj Patel - CEO & C
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates
09:40am, Tuesday, 28'th Oct 2025
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.23 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to a loss of $0.18 per sha
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
07:30am, Tuesday, 28'th Oct 2025
– ARCALYST ® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth – – ARCALYST 2025 expected net product revenue raised to $670 - $675 million –
Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025
04:01pm, Thursday, 23'rd Oct 2025
LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
08:00am, Friday, 17'th Oct 2025
LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases w
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again
01:11pm, Thursday, 16'th Oct 2025
Kiniksa Pharmaceuticals International, plc (KNSA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next qua
Wall Street Analysts Think Kiniksa Pharmaceuticals International, plc (KNSA) Could Surge 29.3%: Read This Before Placing a Bet
10:56am, Tuesday, 14'th Oct 2025
The mean of analysts' price targets for Kiniksa Pharmaceuticals International, plc (KNSA) points to a 29.3% upside in the stock. While this highly sought-after metric has not proven reasonably effecti
5 Biotech Stocks Worth Adding to Your Portfolio Now
10:25am, Tuesday, 23'rd Sep 2025
The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the Unit
